Goldfinch is singularly focused on discovering and developing precision therapies for patients with kidney disease.

Chronic kidney disease is a driver of mortality across age, race, and stage of disease progression, affecting over 1 in 9 people worldwide. It has emerged as a global epidemic and growing problem that places an enormous social and economic burden on patients, their families, and society.

Advances in kidney transplantation and dialysis over half a century ago extended life for patients with kidney failure, yet the current standard of care for patients with kidney disease remains inadequate, and there is an urgent need for new treatment options.

Recent breakthroughs in genetics and biology have generated an unparalleled understanding of the biological pathways that drive kidney disease. Goldfinch is uniquely positioned to translate these discoveries into new therapies that target the molecular causes of kidney disease.


The burden of kidney disease for patients and society





Goldfinch brings together experts in the field and experienced leaders with a shared mission to pioneer new treatments for patients with kidney disease.


Anthony Johnson, M.D.

Chief Executive Officer

Michael Broxson

Chief Business and Operating Officer

Peter Mundel, M.D.

Chief Scientific Officer

Jean-Christophe Harmange, Ph.D.

Senior Vice President of Drug Discovery

Lori Rudolph-Owen, Ph.D.

Senior Vice President of Portfolio Leadership

Maria Beconi, Ph.D.

Vice President of Pharmacology and Non Clinical Development

Curtis Demick

Vice President of Human Resources

Thomas Tibbitts, Ph.D.

Vice President of Computational Discovery

Liron Walsh, M.D.

Vice President of Translational and Clinical Nephrology


Our Founders and Advisors are world-renowned scientists and clinicians at the forefront of kidney biology, genetics, and genomics.

Joseph Bonventre, M.D., Ph.D.

Harvard Medical School, MIT, Brigham and Women's Hospital

Anna Greka, M.D., Ph.D.

The Broad Institute, Harvard Medical School, Brigham and Women’s Hospital

Friedhelm Hildebrandt, M.D.

Harvard Medical School, Boston Children's Hospital

Daniel MacArthur, Ph.D.

The Broad Institute, Harvard Medical School, Massachusetts General Hospital

Peter Mundel, M.D.

Goldfinch Bio

Stefan Somlo, M.D.

Yale School of Medicine


Abbie Celniker, Ph.D.

Chairwoman of Goldfinch Bio and Partner, Third Rock Ventures

Louis Brenner, M.D.

President and Chief Operating Officer, Allena Pharmaceuticals

Neil Exter

Partner, Third Rock Ventures

Anthony Johnson, M.D.

Chief Executive Officer

Frank W. Maddux, M.D., F.A.C.P.

Executive Vice President and Chief Medical Officer, Fresenius Medical Care North America





Goldfinch is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease.


Goldfinch’s Product Engine will industrialize the integration of genetics and kidney biology and confer a differentiated ability to identify, validate, and pursue novel therapeutic targets for kidney disease.





Goldfinch’s therapeutic programs are underscored by strong genetic validation and a deep familiarity of the biological pathways that cause disease. Our initial efforts are focused on focal segmental glomerulosclerosis (FSGS) and polycystic kidney disease (PKD).



Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disorder, is a histopathologic diagnosis characterized by severe scarring of the kidney's filtering units, or glomeruli, leading to an excess of essential proteins spilling into the urine, called proteinuria. FSGS is a leading cause of kidney failure, and patients with diagnosed FSGS are at increased risk of heart attack, stroke and premature death.

Goldfinch is leading the charge to develop treatments targeting the molecular causes of FSGS to drastically improve the lives of patients suffering from this devastating, life-shortening condition.



Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common single gene diseases, affecting more than 600,000 people in the US and 12 million worldwide. The disease is passed on from parent to child, with each child of an affected parent having a 1-in-2 chance of inheriting the disorder, which does not skip generations.

ADPKD patients develop fluid filled cysts in both kidneys that increase in number and size over time, culminating in end stage kidney disease in half of affected individuals by middle age. ADPKD commonly causes liver cysts which arise from bile ducts and can sometimes grow large enough to cause symptoms as well. In the United States, 1 in 20 individuals either on dialysis or with a kidney transplant has ADPKD.

There are no FDA approved therapies specifically targeting ADPKD and no means by which to alter the course of the disease.

Goldfinch is leveraging scientific discoveries based on the known genes that cause ADPKD to discover treatments to alter the course of ADPKD and drastically improve the lives of patients suffering from this chronic and debilitating disease.





It is the patients with kidney disease who will lead us to the understanding of pathways and targets that will drive transformative drug development. To accomplish this, we will partner with patients to build the world’s most comprehensive registry of individuals with molecularly defined kidney disease.

Goldfinch is assembling a database of genetic, genomic and clinical information from consented patients who have provided thousands of DNA samples and anonymized clinical records. Building off of the studies of our founders and partners, we will deeply study DNA and correlate findings with clinical data. We will then use novel computational tools to mine for evidence of the DNA variants that increase risk for kidney disease and suggest new ways to treat and prevent it.





At Goldfinch, we are pioneering a new approach to discover and develop therapeutics for kidney disease that is unprecedented.

Where others see risk, we see opportunity to make an impact and redefine the state of care for patients with kidney disease. We recognize the importance of collaboration, and strive to work alongside patients, clinicians and other partners to empower patients and develop treatments for conditions where no approved therapies exist.

We’re looking for teammates who relish the challenge, and are compelled to leave a positive mark on the lives of colleagues and patients alike.

If this sounds like the community you want to grow with, we invite you to explore our current career opportunities below.


Note to Recruitment Agencies: Please do not forward any agency resumes. Goldfinch Bio is not responsible for any fees related to resumes that are unsolicited.
Equal Opportunity Employer M/F/D/V.